ArticleRevista da Associacao Medica Brasileira (1992)2025
Anti-hepatitis C virus threshold value in predicting hepatitis C virus viremia in hemodialysis patients.
Article in Revista da Associacao Medica Brasileira (1992), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveHepatitis C virus prevalence is higher in hemodialysis patients than in the general population. It is recommended that patients who are detected to be anti-hepatitis C virus seropositive should be dialyzed in separate machines. In patients requiring urgent hemodialysis treatment, anti-hepatitis C virus seropositivity may cause confusion and delay in dialysis sessions.
methodsThe aim of the study was to determine the most appropriate signal-to-cutoff value to predict hepatitis C virus viremia in hemodialysis patients and to evaluate the effect of genotype differences. A total of 12,280 anti-hepatitis C virus results from hemodialysis patients between 2021 and 2024 were examined.
resultsThe mean age of 563 patients included in the study was 57 years, and 330 (58.6%) were male. Of the 563 patients, 68 (12.07%) were true hepatitis C virus patients. The mean age of hepatitis C virus-ribonucleic acid(+) patients was higher than that of the hepatitis C virus-ribonucleic acid(-) group (p<0.018). Anti-hepatitis C virus signal-to-cutoff value was >1 in all true hepatitis C virus patients. Hepatitis C virus-ribonucleic acid was accepted as the gold standard to determine the best threshold value in receiver operating characteristic curve analysis, and the most appropriate signal-to-cutoff value was found to be 2.23. Sensitivity was 98.5%, specificity was 87.1%, positive predictive value was 51.2%, and negative predictive value was 99.8%. 49 (85.96%) of the patients were identified as genotype(-1; the most common subtype was genotype-1b (n=43).
conclusionAnti-hepatitis C virus negativity is a reliable result in hemodialysis patients. If anti-hepatitis C virus signal-to-cutoff ≥2.23 is detected, confirmation by direct hepatitis C virus-ribonucleic acid testing is recommended. In hemodialysis patients with anti-hepatitis C virus signal-to-cutoff values between 1 and 2.23, false positivity should be considered first, and confirmatory tests should be performed if anti-hepatitis C virus is reactive in a second sample.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.